185,732 Shares in Kenvue Inc. $KVUE Purchased by Ieq Capital LLC

Ieq Capital LLC purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 185,732 shares of the company’s stock, valued at approximately $3,549,000.

Other hedge funds have also recently bought and sold shares of the company. Physician Wealth Advisors Inc. raised its position in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Kenvue during the fourth quarter worth approximately $26,000. Johnson Financial Group Inc. acquired a new stake in shares of Kenvue during the second quarter worth approximately $26,000. MV Capital Management Inc. bought a new stake in shares of Kenvue in the fourth quarter worth $28,000. Finally, CoreCap Advisors LLC increased its stake in shares of Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $19.41 on Tuesday. The company has a market cap of $37.27 billion, a PE ratio of 22.30, a P/E/G ratio of 1.36 and a beta of 0.47. The company has a fifty day moving average price of $19.08 and a two-hundred day moving average price of $18.21. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $21.63.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The business had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. During the same period last year, the company posted $0.29 earnings per share. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.3%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is currently 96.55%.

Analyst Ratings Changes

KVUE has been the topic of a number of research analyst reports. UBS Group reduced their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Barclays increased their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Finally, Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average price target of $19.27.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.